Forbion Capital Partners of the Netherlands has appointed two serial entrepreneurs, Ton Logtenberg and Michael Hayden, as venture partners. Both individuals hold executive positions at Forbion portfolio companies.
Dr Logtenberg is chairman of the board of the Forbion portfolio company Synox Therapeutics Ltd. An antibody expert, he was founder and chief executive of Merus NV as well as co-founder and chief scientific officer of Crucell NV which was acquired by Johnson & Johnson Inc in 2011. Dr Hayden is CEO of the Forbion portfolio company Prilenia Therapeutics BV which is developing medicines for neurological diseases. Pior to this, he was head of global R&D and CSO at Teva Pharmaceutical Industries Ltd.
Forbion announced the appointments on 31 March 2022.
Copyright 2022 Evernow Publishing Ltd